RxDoctor Payments Data

Jaspreet Ghumman, DO

Gastroenterology · Clinton Township, MINPI 1225278054

Payments from drug & device makers

$7,284in general payments, 2019–2025

Across 391 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$771
  • Johnson & Johnson$727
  • Pfizer$655
  • Gilead$300
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$7,18599%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,284 in reported general payments places this provider in the 70th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$60,949
Medicare patients
266
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab28$752,597
Humira(Cf) PenAdalimumab26$343,965
Humira(Cf)Adalimumab13$92,694
RinvoqUpadacitinib13$85,728
XifaxanRifaximin21$85,272
LinzessLinaclotide52$45,897
TrulancePlecanatide29$20,200
PentasaMesalamine11$12,985
Mesalamine16$9,615
Dexlansoprazole DrDexlansoprazole22$7,988
Pantoprazole Sodium212$5,085
SutabSod Sulf/Pot Chloride/Mag Sulf29$4,599
Omeprazole200$3,757
CholestyramineCholestyramine (With Sugar)18$2,068
Lansoprazole32$1,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$727$752,59728 claims
AbbVieHumira(Cf), Rinvoq, Linzess$1,989$224,31978 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,047$105,47250 claims
Braintree Laboratories, Inc.Sutab$103$4,59929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →